Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
Thursday at 6 on WRAL: ð¦ Hazardous packages on your doorstep. How 1 billion packages from China bypassed safety inspectionsâand why itâs legal.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Astria Therapeutics, Inc.
< Previous
1
2
Next >
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
October 30, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
October 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
October 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
August 31, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
August 25, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
August 07, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
July 20, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
July 17, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
July 14, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting
June 05, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
May 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
April 28, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Names Andrea Matthews Chief Business Officer
April 19, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 22, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
March 08, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
February 21, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
February 08, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 19, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
December 15, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
December 15, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.